Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)
{{output}}
Background: Ruxolitinib (RUX) suppresses antiviral immunity in patients with hematologic diseases. For steroid-refractory acute graft-versus-host disease (aGVHD), studies have yielded conflicting results regarding whether RUX tre... ...
